|
DENDREON CORP, (DNDN) Stock Research Free Stock Rating
|
|
| |
| Company Profile |
| |
|
Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of targeted therapies for cancer. Its portfolio of product candidates includes therapeutic vaccines, monoclonal antibodies, and small molecules to treat a range of cancers. The company's lead product candidate, Provenge, is a cancer immunotherapy in Phase 3 clinical trial for the treatment of androgen independent prostate cancer. In addition, the company completed Phase 1 clinical trials for Nauvenge (APC8024), a therapeutic vaccine for the treatment of breast, ovarian, and other solid tumors; and conducting Phase 2 trials of Neuvenge in women with metastatic breast cancer. The companys preclinical programs include monoclonal antibodies, therapies targeting the trp-p8 pathway and serine protease and pro-drug product candidates for the treatment of cancer. Dendreon has research and development alliances with Genentech, Inc.; Abgenix, Inc.; and Dyax Corp. Dendreon was formed in 1992 and is headquartered in Seattle, Washington.
|
DENDREON CORP Related |
|
Dendreon Developing therapeutic, cell-based vaccines for the treatment of cancer.
|
|
DNDN: DENDREON CORP Stock Quote Research DENDREON CORP historical prices, historical volume, splits and dividends. ... Option Skews - Dendreon Corp, Advanced Micro Devices Inc, Yingli Green Energy ...
|
|
DNDN DENDREON CORP DNDN (DENDREON CORP): Stock analyses and research by investors on UpDown.com ... PE Ratio: DENDREON CORP (DNDN) News & Analysis. View more ...
|
|
